



শফিক বসাক এন্ড কোং
SHAFIQ BASAK & CO.

CHARTERED ACCOUNTANTS

Partners:

Md. Shafiqul Islam, FCA
Sampad Kumar Basak, FCA
Md. Enayet Ullah, FCA
Sarwar Mahmood, FCA
Sheikh Zahidul Islam, MBA, FCA

CHATTOGRAM OFFICE :

National House (1st Floor),
109, Agrabad Commercial Area,
Chattogram -4100, Bangladesh.
Phone : 880-31-711561
Pho/Fax : 880-31-723680
Web : www.shafiqbasak.com
E-mail: basak_sbc@yahoo.com
basak@shafiqbasak.com

DHAKA OFFICE -(1):

Shatabdi Centre (4th & 6th Floor)
292, Inner Circular Road.
Fakirapool, Motijheel, Dhaka.
Phone/Fax : 880-2-7192098,
Cell: 01730-080666
E-mail : skzislam86@gmail.com
shafiq_basak@yahoo.com
Web : www.shafiqbasak.com

**AUDITOR'S CERTIFICATE REGARDING MONTHLY STATUS REPORT OF
UTILIZATION OF FUND AGAINST INITIAL PUBLIC OFFERING (IPO) OF
INDO-BANGLA PHARMACEUTICALS LTD.
FOR THE MONTH OF DECEMBER-2019**

This is to certify that INDO-BANGLA PHARMACEUTICALS LTD. has received Tk. 200,000,000 (Taka Twenty Crore) only as Initial Public Offering (IPO) proceeds through subscription from 09 August 2018 to 16 August 2018 in the separate Bank Account (Account number 1011360459420) maintaining with Eastern Bank Limited, Principal Branch, Jiban Bima Bhaban 10, Dilkusha C/A, Dhaka-1000. In line with the condition number 4, Part C of the consent letter number BSEC/CI/IPO-260/2016/118 dated: 19 February 2018 of Bangladesh Securities and Exchange Commission (BSEC), fund utilization status as on 31 December 2019 is as follows:

Sl. No.	Purpose of Utilization	Allotment as per IPO (Tk.)	Fund utilized (Taka) up to the month of November 2019	Fund utilized (Taka) for the month of December 2019	Total Utilization of Fund up to November 30, 2019	Unspent Balance (Taka)
1	Machinery	183,300,000	124,720,000	-	124,720,000	58,580,000
2	IPO Expenses	16,700,000	16,700,000	-	16,700,000	-
	Total IPO Proceeds	200,000,000	141,420,000	-	141,420,000	58,580,000

Total fund unutilized amounting to Tk. 5,85,80,000 (Taka: Five Crore Eighty Five Lac Eighty Thousand) only up to 31 December 2019.

We have only confirmed Bank Balance of Tk. 5,24,41,233 vide A/C-111813124288298 with Mercantile Bank Limited Elephant Road Branch as at 30 November 2019. We have been explained by the management that the difference of Tk. 61,38,767 is caused by two LC payments related to machinery which will be adjusted with machinery as per minutes of The 5th Annual General Meeting held on 12th December, 2019 resolution no.08.

We have checked and enclosed Status Report (Annexure-A) of utilization of fund prepared by management.



INDEPENDENT MEMBER OF
ABACUS
WORLDWIDE

DHAKA OFFICE -(2): House - 42 (1st Floor), Road - 01, Book - A, Niketan, Gulshan - 01, Dhaka.
Phone : 88-02-99859602-3, 01819-285196, E-mail.mahmoods.bd@gmail.com

In Practice Since 1993

During the course of our certification, we have found that:

The management of INDO-BANGLA PHARMACEUTICALS LTD. deposited as FDR amount in Tk. 18,33,00,000 (Taka: Eighteen Crore and Thirty Three Lac) only during the month of November 2018 with Mercantile Bank Limited Tk. 10,00,00,000 (Taka: Ten Crore) for 3-6 months period with 9% interest rate per annum and Standard Bank Limited Tk. 8,33,00,000 (Taka: Eight Crore and Thirty Three Lac) for 3 months period with 9% interest rate per annum. We also note that the Company has encashed the whole amount of Tk. 18 Crore and 33 Lac upto the month of November 2019.

We also report that:

- i. the expenses/utilization has been made in line with the provision of Initial Public Offering (IPO) documents (Not applicable for the month of December 2019);
- ii. the expenses/utilization made in line with the condition 4, part C of consent letter of Initial Public Offering (IPO) (Not applicable for the month of December 2019);
- iii. the expenses/utilization Tk. 14,14,20,000 of IPO proceeds have been completed Fifteen (15) months (after the receiving of IPO fund) within 24 (Twenty Four) months mentioned the time schedule/ implementation schedule as specified Initial Public Offering (IPO) documents (Not applicable for the month of December 2019);
- iv. the expenses/utilization made is accurate /for the purpose of the company as mentioned in Initial Public Offering (IPO) documents (Not applicable for the month of December 2019); and
- v. we also confirmed that: (i) expenses have been procured/incurred maintaining proper procedure as well as at a reasonable price; and (ii) books and records including vouchers in support of utilization of Initial Public Offering (IPO) proceeds are found correct (Not applicable for the month of December 2019).

Dated: 14 January 2020

Place: Dhaka



Shafiq Basak & Co.
SHAFIQ BASAK & CO.
Chartered Accountants

Report on Utilization of IPO Proceeds for the month of December-2019


Name of the Company : INDO-BANGLA PHARMACEUTICALS LTD.
 Amount (BDT) of Capital Raised Through IPO : BDT. 200,000,000.00
 Date of Trading : October 18, 2018
 Last Date of Full Utilization of Fund as per Proceeds : October 17, 2020 (within 24 Months of obtaining IPO proceeds)

Sl. No.	Purpose Mentioned in the Prospectus	Time line as per prospectus	Amount as per prospectus	Status of Utilization				Remarks		
				Fund utilization (Taka) up to the month of November 2019	Fund utilized (Taka) for the month of December 2019	Total Utilized Amount	Utilized %		Total Un-utilized Amount	Un-utilized %
1	Machinery	24 Months	183,300,000	124,720,000	-	124,720,000	68.04%	58,580,000	31.96%	IPO Utilization proceeds Certified by Shafig Basak & CO., Chartered Accountants
2	IPO Expenses	As or when required	16,700,000	16,700,000	-	16,700,000	100.00%	-	0.00%	
Total IPO Proceeds			200,000,000	141,420,000	-	141,420,000		58,580,000		

Note:

- * BDT 51,262 has been charged by the bank as maintenance fee and others of IPO proceeds accounts (A/C No.1011360459420 maintaining with Estem Bank Limited) upto the month of December 2019.
- * Fund utilization period have been extended to 24 months instead of 18 months for construction and other civil works due to changes of Factory place and subsequently approved by the Board of Director and Shareholders in 4th Annual General Meeting.
- * Fund utilization fixed for Construction and other Civil works has been change to Machinery has been subsequently approved by the Board of Director and Shareholders in 5th Annual General Meeting.


Chairman


Managing Director


Company Secretary


Chief Financial Officer

